AAP
LRMR icon

Arax Advisory Partners’s Larimar Therapeutics LRMR Stock Holding History

Arax Advisory Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.6K Buy
11,988
+11,831
+7,536% +$47K ﹤0.01% 3522
2026
Q1 		$707 Buy
157
+147
+1,470% +$588 ﹤0.01% 3359
2025
Q4 		$38 Sell
10
-10,915
-100% -$42.5K ﹤0.01% 3963
2025
Q3 		$35.3K Buy
+10,925
New +$41K ﹤0.01% 2006
2025
Q1 		– Sell
-405
Closed -$1.57K – 2891
2024
Q4 		$1.57K Buy
405
+119
+42% +$786 ﹤0.01% 2064
2024
Q3 		$1.87K Hold
286
– – ﹤0.01% 2088
2024
Q2 		$2.07K Buy
+286
New +$2.19K ﹤0.01% 1952

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Arax Advisory Partners's LRMR Position: Q2 2026 in Review

Arax Advisory Partners increased its Larimar Therapeutics (LRMR) stake by 7,536% in Q2 2026, buying an estimated $47K and bringing the position to 11,988 shares worth $36.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3522.

Arax Advisory Partners first reported a position in LRMR in Q2 2024 and has held it in 7 quarters since. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Arax Advisory Partners held 11,988 shares of Larimar Therapeutics worth $36.6K as of Q2 2026.
  • Arax Advisory Partners bought 11,831 Larimar Therapeutics shares in Q2 2026, an estimated $47K.
  • Larimar Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3522 holding.
  • Arax Advisory Partners first reported a position in Larimar Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.